These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 6091392)

  • 21. Further clinical experiences of a phase I study with the hypoxic cell radiosensitizer misonidazole.
    Kogelnik HD; Meyer JH; Jentzsch K; Szepesi T; Kärcher KH; Maida E; Mamoli B; Wessely P; Zaunbauer F
    Br J Cancer Suppl; 1978 Jun; 3():281-5. PubMed ID: 209810
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Final report on the United States Phase I Clinical Trial of the hypoxic cell radiosensitizer, misonidazole (Ro-07-0582; NSC #261037).
    Phillips TL; Wasserman TH; Johnson RJ; Levin VA; VanRaalte G
    Cancer; 1981 Oct; 48(8):1697-704. PubMed ID: 6269723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I study of misonidazole and pelvic irradiation in patients with carcinoma of cervix.
    Thomas GM; Rauth AM; Black BE; Cummings BJ; Sorenti VL; Bush RS
    Br J Cancer; 1982 Jun; 45(6):860-8. PubMed ID: 6284190
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fatal misonidazole-induced encephalopathy: an RTOG case report.
    Kun LE; Ho KC; Moulder JE
    Cancer; 1982 Feb; 49(3):423-6. PubMed ID: 7059905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of misonidazole in association with a three-fractions per day regimen in advanced head and neck epidermoid cancer. A pilot study.
    Awwad HK; Barsoum M; El Merzabani M; Omar S; El Badawy S; Ezzat S; El Baki HA; Zaki A
    Am J Clin Oncol; 1983 Feb; 6(1):91-7. PubMed ID: 6301258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Postoperative radiotherapy of astrocytomas grade 3 and 4 with the radiosensitizer misonidazole. -End results of a multicentric controlled German study].
    Sack H; Calcanis A; Godehardt E; Weidtman V; Zülch KJ; Ammon J; Bamberg M; Herbst M; Keim H; Kleibel F; Makoski HB; Potthoff PC; Schlegel G; Schnepper E
    Strahlentherapie; 1982 Aug; 158(8):466-9. PubMed ID: 6753245
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Large fraction radiotherapy plus misonidazole for treatment of advanced lung cancer: report of a phase I/II trial.
    Simpson JR; Perez CA; Phillips TL; Concannon JP; Carella RJ
    Int J Radiat Oncol Biol Phys; 1982 Feb; 8(2):303-8. PubMed ID: 7085386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical study on radiotherapy in combination with misonidazole].
    Ono K; Takahashi M; Dodo Y; Abe M
    Nihon Gan Chiryo Gakkai Shi; 1983 Aug; 18(5):1189-99. PubMed ID: 6663172
    [No Abstract]   [Full Text] [Related]  

  • 29. Peripheral electrophysiological parameters in mice treated with misonidazole.
    Von Burg R; Conroy PJ; Passalacqua W
    Br J Cancer; 1979 Jul; 40(1):134-43. PubMed ID: 454559
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New side effect of the hypoxic cell sensitizer, misonidazole.
    Partington J; Koziol D; Chapman D; Rabin H; Urtasun RC
    Cancer Treat Rep; 1979 Jan; 63(1):123-5. PubMed ID: 217536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Misonidazole in the preoperative and radical radiotherapy of bladder cancer.
    Awwad HK; El Merzabani MM; El Badawy S; Ezzat S; Akoush H; Abd El Moneim H; Saiid A; Soliman O; Khafagy M; Burgers MV
    Cancer Clin Trials; 1980; 3(3):275-80. PubMed ID: 7438324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Skin rashes associated with the administration of the 2-nitroimidazole, misonidazole.
    Saunders MI; Dische S; Kogelnik HD; Sealy R; Lenox-Smith I
    Cancer Treat Rep; 1980; 64(2-3):263-8. PubMed ID: 6447539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of misonidazole peripheral neurotoxicity in rats by analysis of nerve trains evoked response.
    Edwards MS; Bolger CA; Levin VA; Phillips TL; Jewett DL
    Int J Radiat Oncol Biol Phys; 1982 Jan; 8(1):69-74. PubMed ID: 6277833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The optimum regime for the administration of misonidazole and the establishment of multi-centre clinical trials.
    Dische S; Saunders MI; Flockhart IR
    Br J Cancer Suppl; 1978 Jun; 3():318-21. PubMed ID: 209811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kinetic aspects of misonidazole and its major metabolite in radiotherapy.
    Meering PG; Gonzalez DG; Maes RA; van Peperzeel HA
    Hum Toxicol; 1985 Jul; 4(4):425-34. PubMed ID: 4018823
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phenytoin neuropathy: structural changes in the sural nerve.
    Ramirez JA; Mendell JR; Warmolts JR; Griggs RC
    Ann Neurol; 1986 Feb; 19(2):162-7. PubMed ID: 3008637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Electrophysiologic study in peripheral neuropathy associated with HIV infection.
    Cruz Martínez A; Villoslada C
    Electromyogr Clin Neurophysiol; 1991; 31(7):407-14. PubMed ID: 1660806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pilot study of radiotherapy with misonidazole in head and neck cancer.
    Paterson IC; Dawes PJ; Henk JM; Moore JL
    Clin Radiol; 1981 Mar; 32(2):225-9. PubMed ID: 7214840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A study of the effect of misonidazole in conjunction with radiotherapy for the treatment of grades 3 and 4 astrocytomas. A report from the MRC Working Party on misonidazole in gliomas.
    Br J Radiol; 1983 Sep; 56(669):673-82. PubMed ID: 6309314
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical experience with daily doses of misonidazole (author's transl)].
    Kogelnik HD; Reinartz G; Szepesi T; Seitz W; Wurst F; Mamoli B; Wessely P; Stark H
    Strahlentherapie; 1980 Nov; 156(11):758-64. PubMed ID: 7434385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.